Over 60 million people struggle with the addictive effects of opioids globally, and more than 100,000 people die every year of opioid overdose, many of them due to fentanyl.1 As the rates continue to increase, new harm reduction and overdose prevention strategies are necessary to help communities mitigate this ongoing crisis.
A new white paper describes the current gaps and opportunities related to fentanyl testing necessary to improve and support local overdose prevention efforts.
The use of FDA-approved fentanyl urine drug screens within dedicated and healthcare populations is important for identifying at-risk individuals and populations and vital in identifying local trends and responding to changing needs to help alter the trajectory of the overdose epidemic.
